Drug intelligence / Profile preview

STC2714

Development stage: Unknown
Lead developer: Staidson Biopharmaceutical
Modality: Small Molecules

Overview

STC2714 is a small molecule modulator of the sphingosine-1-phosphate receptor 1 (S1P1) currently under development by Staidson Pharma (Staidson Hongkong). The drug's mechanism of action involves the modulation of S1P1 receptors on lymphocytes, which leads to their sequestration within lymph nodes. This process prevents the egress of inflammatory cells into the systemic circulation and their subsequent infiltration into target tissues, thereby reducing inflammatory activity. STC2714 is being investigated for the treatment of several inflammatory and autoimmune conditions, including ulcerative colitis, Crohn's disease, and gout.

Targets

EDG1 (Sphingosine-1-phosphate receptors)

Beyond the preview

Go deeper on STC2714.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on STC2714.

Explore the full profile